Interleukin-10 rs1800896 polymorphism is associated with increased head and neck cancer risk but not associated with its clinical stages

BACKGROUND: The association of interleukin-10 rs1800896 polymorphism with head and neck cancer risk and its clinical stages has been investigated by many published studies, but the results remain inconsistent. Therefore, we conducted this meta-analysis for further investigation. RESULTS: Six case-control studies involving 1,781 head and neck cancer patients and 1,978 controls were yielded. The results indicated an association between rs1800896 polymorphism and increased head and neck risk [odds ratio (95%confidence interval) for G vs. A, GA vs. AA, GG vs. AA, GA+GG vs. AA, and GG vs. AA + GA were 1.63 (1.30–2.04), 3.17 (2.11–4.76), 1.63 (1.17–2.26), 1.73 (1.25–2.39), and 2.73 (1.82–4.09), respectively]. The subgroup analyses all obtained similar results with overall populations. The results of clinical stages yielded a non-significant association. No publication bias was detected. MATERIALS AND METHODS: The PubMed and Chinese National Knowledge Infrastructure databases were searched up to December 27, 2016. Two authors independently selected studies, extracted and analyzed the data using the RevMan 5 software. Either a fixed effect or a random effect model was used to estimate pooled odds ratio and its 95% confidence intervals. CONCLUSIONS: We concluded that interleukin-10 rs1800896 polymorphism was significantly associated with head and neck cancer risk but not with the clinical stages thereof.